Physician profile
Cassi Brie Smithem
NPI 1730810961
$3,520.32
in general payments reported to CMS, 2019-2025
19 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $771 · 2024: $2,190 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.71 |
| Education | $316.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.85 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $622.50 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $345.87 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $331.04 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $272.04 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $244.01 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $134.49 | 2023-2024 | Tremfya |
| Amgen INC. | $127.69 | 2023-2024 | Otezla |
| Leo Pharma INC. | $99.62 | 2024-2025 | Adbry |
| Dermavant Sciences, INC. | $95.45 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $84.80 | 2024 | |
| Genzyme Corporation | $79.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $54.48 | 2024 | |
| Arcutis Biotherapeutics, INC. | $53.06 | 2024-2025 | Zoryve |
| Pfizer INC. | $38.38 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $20.84 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.96 | 2024 | Spevigo |
| Organon LLC | $16.04 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $15.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassi Smithem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.